Dehao Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dehao Fu has a total of 119 co-authors. Here are the top co-authors by number of shared publications:
Yuanyuan Guo
Huazhong University of Science and Technology
9 shared publicationsYongzhi Cui
Department of Orthopedic Surgery, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200233, China
7 shared publications- Yuanyuan Guo
Department of Pharmacy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
7 shared publications Jingyu Shi
Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 shared publicationsPing Liu
Department of Orthopaedics, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publicationsWeihang Gao
Department of Orthopaedics, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China
5 shared publications
Latest Publications
- Open Access
- 27 September 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
Osteosarcopenia and stability of fragility pelvic fractures in elderly women
- 27 September 2026
- Published by Springer Nature in Aging Clinical and Experimental Research
Open AccessOsteosarcopenia and stability of fragility pelvic fractures in elderly women
- 18 July 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 255, 307-318
Dual-regulation of mitophagy and cytosolic mtDNA-induced inflammation for the treatment of inflammatory bone loss
- 18 July 2026
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 255, 307-318
Dual-regulation of mitophagy and cytosolic mtDNA-induced inflammation for the treatment of inflammatory bone loss
- Top Cited PapersOpen Access
- 16 March 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Dual-targeted hybrid nanovesicles coordinated bone-muscle regeneration via regulating the DUSP4/p38 MAPK pathway to reverse osteosarcopenia
Osteosarcopenia (OSP), a degenerative syndrome characterized by concurrent osteoporosis and sarcopenia, exhibits persistently high global prevalence due to
- 16 March 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Top Cited PapersOpen AccessDual-targeted hybrid nanovesicles coordinated bone-muscle regeneration via regulating the DUSP4/p38 MAPK pathway to reverse osteosarcopenia
Osteosarcopenia (OSP), a degenerative syndrome characterized by concurrent osteoporosis and sarcopenia, exhibits persistently high global prevalence due to
- Open Access
- 4 February 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 7 (2) , 158-163
Trochlear dysplasia is associated with distal patellar fracture
Aims: While trochlear dysplasia is recognized as a key factor in patellar instability, its association with specific patellar fracture patterns remains unclear. This study investigates the relationship between trochlear dysplasia and patellar fractures through morphological analysis. Methods: In this prospective cohort study of 318 patients with acute patellar fractures (January to June 2021), preoperative CT scans were analyzed for trochlear dysplasia parameters: sulcus angle, trochlear depth, and lateral trochlear inclination. Fractures were classified using AO/Orthopaedic Trauma Association (OTA) criteria with emphasis on inferior pole involvement. Multivariable logistic regression was used to identify morphological predictors of fracture type. Results: Trochlear dysplasia was identified in 152 (47.80%) of patients, with a mean sulcus angle of 144.44° (SD 11.16°), trochlear depth of 4.43 mm (SD 1.33), and lateral trochlear inclination of 18.25° (SD 4.89°). Fractures classified as AO/OTA types A and C1.3 were more prevalent in patients with trochlear dysplasia. Logistic regression analysis showed that the sulcus angle significantly influenced the occurrence of the distal fractures (p < 0.001, odds ratio (OR) = 1.15, 95% CI 1.111 to 1.187). Conclusion: Trochlear dysplasia, particularly manifested by an increased sulcus angle, is significantly associated with distal patellar fractures. These findings highlight the importance of preoperative morphological assessment in predicting fracture patterns and tailoring clinical management. Cite this article: Bone Jt Open 2026;7(2):158–163.
- 4 February 2026
- Published by British Editorial Society of Bone & Joint Surgery in Bone & Joint Open
- Vol. 7 (2) , 158-163
Open AccessTrochlear dysplasia is associated with distal patellar fracture
Aims: While trochlear dysplasia is recognized as a key factor in patellar instability, its association with specific patellar fracture patterns remains unclear. This study investigates the relationship between trochlear dysplasia and patellar fractures through morphological analysis. Methods: In this prospective cohort study of 318 patients with acute patellar fractures (January to June 2021), preoperative CT scans were analyzed for trochlear dysplasia parameters: sulcus angle, trochlear depth, and lateral trochlear inclination. Fractures were classified using AO/Orthopaedic Trauma Association (OTA) criteria with emphasis on inferior pole involvement. Multivariable logistic regression was used to identify morphological predictors of fracture type. Results: Trochlear dysplasia was identified in 152 (47.80%) of patients, with a mean sulcus angle of 144.44° (SD 11.16°), trochlear depth of 4.43 mm (SD 1.33), and lateral trochlear inclination of 18.25° (SD 4.89°). Fractures classified as AO/OTA types A and C1.3 were more prevalent in patients with trochlear dysplasia. Logistic regression analysis showed that the sulcus angle significantly influenced the occurrence of the distal fractures (p < 0.001, odds ratio (OR) = 1.15, 95% CI 1.111 to 1.187). Conclusion: Trochlear dysplasia, particularly manifested by an increased sulcus angle, is significantly associated with distal patellar fractures. These findings highlight the importance of preoperative morphological assessment in predicting fracture patterns and tailoring clinical management. Cite this article: Bone Jt Open 2026;7(2):158–163.
- Open Access
- 22 May 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-8
Separate vertical wiring versus conventional tension band fixation for inferior pole patellar fractures: a prospective cohort study on postoperative patella baja and functional outcomes
To compare the clinical efficacy of the separate vertical wiring (SVW) technique and conventional tension band fixation in managing AO/OTA type A1 inferior pole patellar fractures, focusing on postoperative patella baja incidence and functional recovery. From January 2019 to January 2023, 242 patients with AO/OTA A1 inferior pole patellar fractures undergoing surgical treatment were assigned to the SVW group (n = 117) or tension band (TB) group (n = 125). The primary outcome was the incidence of patella baja (Insall-Salvati index < 0.8) at the 12-month follow-up. Secondary outcomes included knee range of motion (ROM), Böstman functional score, and complications. The SVW group demonstrated a significantly lower incidence of patella baja compared to the TB group (25.6% vs. 52.1%, P < 0.001), with higher mean (Insall-Salvati index) ISI values (0.87 ± 0.16 vs. 0.76 ± 0.12, P < 0.01). Knee ROM was superior in the SVW group (124.0°±14.2° vs. 119.9°±12.4°, P = 0.017), though no significant difference was observed in Böstman scores (25.1 ± 3.5 vs. 24.6 ± 3.6, P = 0.33). The overall complication rate was 5.8% (14/242), primarily comprising surgical site infections (3.5%, 8/242: 1.2% superficial, 2.1% deep), fixation failure (1.2%, 3/242), and nonunion (0.8%, 2/242). Notably, soft tissue irritation occurred exclusively in the TB group (8.8%, 11/125 vs. 0% in SVW; P = 0.005). The SVW technique significantly reduces the risk of patella baja and improves knee range of motion by optimizing vertical tension distribution, establishing it as a biomechanically superior fixation strategy for AO/OTA A1 inferior pole patellar fractures. These findings support SVW as a first-line treatment for such complex injuries.
- 22 May 2025
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-8
Open AccessSeparate vertical wiring versus conventional tension band fixation for inferior pole patellar fractures: a prospective cohort study on postoperative patella baja and functional outcomes
To compare the clinical efficacy of the separate vertical wiring (SVW) technique and conventional tension band fixation in managing AO/OTA type A1 inferior pole patellar fractures, focusing on postoperative patella baja incidence and functional recovery. From January 2019 to January 2023, 242 patients with AO/OTA A1 inferior pole patellar fractures undergoing surgical treatment were assigned to the SVW group (n = 117) or tension band (TB) group (n = 125). The primary outcome was the incidence of patella baja (Insall-Salvati index < 0.8) at the 12-month follow-up. Secondary outcomes included knee range of motion (ROM), Böstman functional score, and complications. The SVW group demonstrated a significantly lower incidence of patella baja compared to the TB group (25.6% vs. 52.1%, P < 0.001), with higher mean (Insall-Salvati index) ISI values (0.87 ± 0.16 vs. 0.76 ± 0.12, P < 0.01). Knee ROM was superior in the SVW group (124.0°±14.2° vs. 119.9°±12.4°, P = 0.017), though no significant difference was observed in Böstman scores (25.1 ± 3.5 vs. 24.6 ± 3.6, P = 0.33). The overall complication rate was 5.8% (14/242), primarily comprising surgical site infections (3.5%, 8/242: 1.2% superficial, 2.1% deep), fixation failure (1.2%, 3/242), and nonunion (0.8%, 2/242). Notably, soft tissue irritation occurred exclusively in the TB group (8.8%, 11/125 vs. 0% in SVW; P = 0.005). The SVW technique significantly reduces the risk of patella baja and improves knee range of motion by optimizing vertical tension distribution, establishing it as a biomechanically superior fixation strategy for AO/OTA A1 inferior pole patellar fractures. These findings support SVW as a first-line treatment for such complex injuries.
- Open Access
- 19 December 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-19
Apoptotic body based biomimetic hybrid nanovesicles to attenuate cytokine storms for sepsis treatment
Sepsis is a severe immune response to pathogens that is associated with high mortality rate and a paucity of efficacious treatment options. It is characterized by the hyperactivation of macrophages and the occurrence of cytokine storms. Given the anti-inflammatory properties of M2 macrophages and their derived apoptotic bodies (AB), as well as the specific uptake of these by macrophages, a novel approach was employed to combine AB with artificial liposomes to create apoptotic body based biomimetic hybrid nanovesicles (L-AB). The L-AB effectively inherited “eat me” signaling molecules on the surface of the AB, thereby facilitating their targeted uptake by macrophages in both in vitro and in vivo settings. The administration of L-AB for the delivery of dexamethasone effectively augmented the therapeutic efficacy of the drug, mitigated macrophage hyperactivation and tissue damage in vivo, and consequently enhanced the survival rate of septic mice. Taken together, these findings suggest that the apoptotic body biomimetic nanovesicles may represent a potential drug delivery system capable of specifically targeting macrophages for the treatment of sepsis.
- 19 December 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-19
Open AccessApoptotic body based biomimetic hybrid nanovesicles to attenuate cytokine storms for sepsis treatment
Sepsis is a severe immune response to pathogens that is associated with high mortality rate and a paucity of efficacious treatment options. It is characterized by the hyperactivation of macrophages and the occurrence of cytokine storms. Given the anti-inflammatory properties of M2 macrophages and their derived apoptotic bodies (AB), as well as the specific uptake of these by macrophages, a novel approach was employed to combine AB with artificial liposomes to create apoptotic body based biomimetic hybrid nanovesicles (L-AB). The L-AB effectively inherited “eat me” signaling molecules on the surface of the AB, thereby facilitating their targeted uptake by macrophages in both in vitro and in vivo settings. The administration of L-AB for the delivery of dexamethasone effectively augmented the therapeutic efficacy of the drug, mitigated macrophage hyperactivation and tissue damage in vivo, and consequently enhanced the survival rate of septic mice. Taken together, these findings suggest that the apoptotic body biomimetic nanovesicles may represent a potential drug delivery system capable of specifically targeting macrophages for the treatment of sepsis.
- Open Access
- 30 April 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-18
Ångstrom-scale gold particles loaded with alendronate via alpha-lipoic acid alleviate bone loss in osteoporotic mice
Osteoporosis is a highly prevalent metabolic disease characterized by low systemic bone mass and deterioration of bone microarchitecture, resulting in reduced bone strength and increased fracture risk. Current treatment options for osteoporosis are limited by factors such as efficacy, cost, availability, side effects, and acceptability to patients. Gold nanoparticles show promise as an emerging osteoporosis therapy due to their osteogenic effects and ability to allow therapeutic delivery but have inherent constraints, such as low specificity and the potential for heavy metal accumulation in the body. This study reports the synthesis of ultrasmall gold particles almost reaching the Ångstrom (Ång) dimension. The antioxidant alpha-lipoic acid (LA) is used as a dispersant and stabilizer to coat Ångstrom-scale gold particles (AuÅPs). Alendronate (AL), an amino-bisphosphonate commonly used in drug therapy for osteoporosis, is conjugated through LA to the surface of AuÅPs, allowing targeted delivery to bone and enhancing antiresorptive therapeutic effects. In this study, alendronate-loaded Ångstrom-scale gold particles (AuÅPs-AL) were used for the first time to promote osteogenesis and alleviate bone loss through regulation of the WNT signaling pathway, as shown through in vitro tests. The in vivo therapeutic effects of AuÅPs-AL were demonstrated in an established osteoporosis mouse model. The results of Micro-computed Tomography, histology, and tartrate-resistant acid phosphatase staining indicated that AuÅPs-AL significantly improved bone density and prevented bone loss, with no evidence of nanoparticle-associated toxicity. These findings suggest the possible future application of AuÅPs-AL in osteoporosis therapy and point to the potential of developing new approaches for treating metabolic bone diseases using Ångstrom-scale gold particles.
- 30 April 2024
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-18
Open AccessÅngstrom-scale gold particles loaded with alendronate via alpha-lipoic acid alleviate bone loss in osteoporotic mice
Osteoporosis is a highly prevalent metabolic disease characterized by low systemic bone mass and deterioration of bone microarchitecture, resulting in reduced bone strength and increased fracture risk. Current treatment options for osteoporosis are limited by factors such as efficacy, cost, availability, side effects, and acceptability to patients. Gold nanoparticles show promise as an emerging osteoporosis therapy due to their osteogenic effects and ability to allow therapeutic delivery but have inherent constraints, such as low specificity and the potential for heavy metal accumulation in the body. This study reports the synthesis of ultrasmall gold particles almost reaching the Ångstrom (Ång) dimension. The antioxidant alpha-lipoic acid (LA) is used as a dispersant and stabilizer to coat Ångstrom-scale gold particles (AuÅPs). Alendronate (AL), an amino-bisphosphonate commonly used in drug therapy for osteoporosis, is conjugated through LA to the surface of AuÅPs, allowing targeted delivery to bone and enhancing antiresorptive therapeutic effects. In this study, alendronate-loaded Ångstrom-scale gold particles (AuÅPs-AL) were used for the first time to promote osteogenesis and alleviate bone loss through regulation of the WNT signaling pathway, as shown through in vitro tests. The in vivo therapeutic effects of AuÅPs-AL were demonstrated in an established osteoporosis mouse model. The results of Micro-computed Tomography, histology, and tartrate-resistant acid phosphatase staining indicated that AuÅPs-AL significantly improved bone density and prevented bone loss, with no evidence of nanoparticle-associated toxicity. These findings suggest the possible future application of AuÅPs-AL in osteoporosis therapy and point to the potential of developing new approaches for treating metabolic bone diseases using Ångstrom-scale gold particles.
- Open Access
- 22 January 2024
- Published by Springer Nature in Research Square
Ångstrom-scale gold particles loaded with alendronate via alpha- lipoic acid alleviate bone loss in osteoporotic mice
Osteoporosis is a highly prevalent metabolic disease characterized by low systemic bone mass and deterioration of bone microarchitecture, resulting in reduced bone strength and increased fracture risk. Current treatment options for osteoporosis are limited by factors such as efficacy, cost, availability, side effects, and acceptability to patients. Gold nanoparticles show promise as an emerging osteoporosis therapy due to their osteogenic effects and ability to allow therapeutic delivery but have inherent constraints, such as low specificity and the potential for heavy metal accumulation in the body. This study reports the synthesis of ultrasmall gold particles almost reaching the Ångstrom (Ång) dimension. The antioxidant alpha-lipoic acid (LA) is used as a dispersant and stabilizer to coat Ångstrom-scale gold particles (AuÅPs). Alendronate (AL), an amino-bisphosphonate commonly used in drug therapy for osteoporosis, is conjugated through LA to the surface of AuÅPs, allowing targeted delivery to bone and enhancing antiresorptive therapeutic effects. In this study, alendronate-loaded Ångstrom-scale gold particles (AuÅPs-AL) were used for the first time to promote osteogenesis and alleviate bone loss through regulation of the WNT signaling pathway, as shown through in vitro tests. The in vivo therapeutic effects of AuÅPs-AL were demonstrated in an established osteoporosis mouse model. Microcomputed tomography, histology, and tartrate-resistant acid phosphatase staining indicated that AuÅPs-AL significantly improved bone density and prevented bone loss, with no evidence of nanoparticle-associated toxicity. These findings suggest the possible future application of AuÅPs-AL in osteoporosis therapy and point to the potential of developing new approaches for treating metabolic bone diseases using Ångstrom-scale gold particles.
- 22 January 2024
- Published by Springer Nature in Research Square
Open AccessÅngstrom-scale gold particles loaded with alendronate via alpha- lipoic acid alleviate bone loss in osteoporotic mice
Osteoporosis is a highly prevalent metabolic disease characterized by low systemic bone mass and deterioration of bone microarchitecture, resulting in reduced bone strength and increased fracture risk. Current treatment options for osteoporosis are limited by factors such as efficacy, cost, availability, side effects, and acceptability to patients. Gold nanoparticles show promise as an emerging osteoporosis therapy due to their osteogenic effects and ability to allow therapeutic delivery but have inherent constraints, such as low specificity and the potential for heavy metal accumulation in the body. This study reports the synthesis of ultrasmall gold particles almost reaching the Ångstrom (Ång) dimension. The antioxidant alpha-lipoic acid (LA) is used as a dispersant and stabilizer to coat Ångstrom-scale gold particles (AuÅPs). Alendronate (AL), an amino-bisphosphonate commonly used in drug therapy for osteoporosis, is conjugated through LA to the surface of AuÅPs, allowing targeted delivery to bone and enhancing antiresorptive therapeutic effects. In this study, alendronate-loaded Ångstrom-scale gold particles (AuÅPs-AL) were used for the first time to promote osteogenesis and alleviate bone loss through regulation of the WNT signaling pathway, as shown through in vitro tests. The in vivo therapeutic effects of AuÅPs-AL were demonstrated in an established osteoporosis mouse model. Microcomputed tomography, histology, and tartrate-resistant acid phosphatase staining indicated that AuÅPs-AL significantly improved bone density and prevented bone loss, with no evidence of nanoparticle-associated toxicity. These findings suggest the possible future application of AuÅPs-AL in osteoporosis therapy and point to the potential of developing new approaches for treating metabolic bone diseases using Ångstrom-scale gold particles.
- Top Cited Papers
Bone‐Targeted Biomimetic Nanogels Re‐Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis
Insufficient bone formation and excessive bone resorption caused by estrogen deficiency are the major factors resulting in the incidence of postmenopausal osteoporosis (PMOP). The existing drugs usually fail to re‐establish the osteoblast/osteoclast balance from both sides and generate side‐effects owing to the lack of bone‐targeting ability. Here, engineered cell‐membrane‐coated nanogels PNG@mR&C capable of scavenging receptor activator of nuclear factor‐κB ligand (RANKL) and responsively releasing therapeutic PTH 1–34 in the bone microenvironment are prepared from RANK and CXCR4 overexpressed bone mesenchymal stem cell (BMSC) membrane‐coated chitosan biopolymers. The CXCR4 on the coated‐membranes confer bone‐targeting ability, and abundant RANK effectively absorb RANKL to inhibit osteoclastogenesis. Meanwhile, the release of PTH 1–34 triggered by osteoclast‐mediated acid microenvironment promote osteogenesis. In addition, the dose and frequency are greatly reduced due to the smart release property, prolonged circulation time, and bone‐specific accumulation. Thus, PNG@mR&C exhibits satisfactory therapeutic effects in the ovariectomized (OVX) mouse model. This study provides a new paradigm re‐establishing the bone metabolic homeostasis from multitargets and shows great promise for the treatment of PMOP.
Top Cited PapersBone‐Targeted Biomimetic Nanogels Re‐Establish Osteoblast/Osteoclast Balance to Treat Postmenopausal Osteoporosis
Insufficient bone formation and excessive bone resorption caused by estrogen deficiency are the major factors resulting in the incidence of postmenopausal osteoporosis (PMOP). The existing drugs usually fail to re‐establish the osteoblast/osteoclast balance from both sides and generate side‐effects owing to the lack of bone‐targeting ability. Here, engineered cell‐membrane‐coated nanogels PNG@mR&C capable of scavenging receptor activator of nuclear factor‐κB ligand (RANKL) and responsively releasing therapeutic PTH 1–34 in the bone microenvironment are prepared from RANK and CXCR4 overexpressed bone mesenchymal stem cell (BMSC) membrane‐coated chitosan biopolymers. The CXCR4 on the coated‐membranes confer bone‐targeting ability, and abundant RANK effectively absorb RANKL to inhibit osteoclastogenesis. Meanwhile, the release of PTH 1–34 triggered by osteoclast‐mediated acid microenvironment promote osteogenesis. In addition, the dose and frequency are greatly reduced due to the smart release property, prolonged circulation time, and bone‐specific accumulation. Thus, PNG@mR&C exhibits satisfactory therapeutic effects in the ovariectomized (OVX) mouse model. This study provides a new paradigm re‐establishing the bone metabolic homeostasis from multitargets and shows great promise for the treatment of PMOP.
- Open Access
- 22 September 2023
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 18 (1) , 1-14
LncRNA MSTRG.22719.16 mediates the reduction of enoxaparin sodium high-viscosity bone cement-induced thrombosis by targeting the ocu-miR-326-5p/CD40 axis
Objective: Polymethylmethacrylate (PMMA) bone cement promotes the development of local thrombi. Our study found that a novel material, ES-PMMA bone cement, can reduce local thrombosis. We used a simple and reproducible animal model to confirm the reduction in local thrombosis and explored the associated molecular mechanism. Methods: New Zealand rabbits, which were used to model thrombosis using extracorporeal carotid artery shunts, were divided into the following two groups, with 3 rabbits in each group: the PMMA bone cement group and the ES-PMMA bone cement group. Four hours after modelling, experimental samples, including thrombotic and vascular tissues, were collected. Thrombotic samples from the PMMA group and ES-PMMA group were subjected to lncRNA sequencing, and a lncRNA microarray was used to screen the differentially expressed lncRNAs. The expression of thrombomodulin in endothelial cells was quantified in vascular tissue samples. Differences in the lncRNA expression profiles between the thrombotic samples of the PMMA group and ES-PMMA group were assessed by base-to-base alignment in the intergenic regions of genomes. The lncRNA-miRNA-mRNA competitive endogenous RNA (ceRNA) network was established in light of ceRNA theory. Thrombosis was observed in the PMMA group and ES-PMMA group. Results: The thrombotic weight was 0.00706 ± 0.00136 g/cm in the PMMA group and 0.00551 ± 0.00115 g/cm in the ES-PMMA group. Quantitative real-time polymerase chain reaction (RT–q-CR) and Western blotting revealed that the expression of CD40, which can regulate thrombosis in vascular endothelial cells, was significantly lower in the ES-PMMA group than in the PMMA group. High-throughput sequencing was used to identify 111 lncRNAs with lower expression in the ES-PMMA group than in the PMMA group. Through bioinformatics investigation, lncRNA MSTRG22719.16/ocu-miR-326-5p/CD40 binding sites were selected. Fluorescent in situ RNA hybridization (FISH) was performed to verify the lower expression of lncRNA MSTRG.22719.16 in vascular tissues from the ES-PMMA group. A dual-luciferase reporter gene assay was applied to verify that ocu-miR-326-5p binds the CD40 3ʹ-UTR and targets lncRNA MSTRG.22719.16. Conclusion: Compared with PMMA bone cement, ES-PMMA bone cement can reduce thrombosis through the lncRNA MSTRG.22719.16/ocu-miR-326-5p/CD40 axis.
- 22 September 2023
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 18 (1) , 1-14
Open AccessLncRNA MSTRG.22719.16 mediates the reduction of enoxaparin sodium high-viscosity bone cement-induced thrombosis by targeting the ocu-miR-326-5p/CD40 axis
Objective: Polymethylmethacrylate (PMMA) bone cement promotes the development of local thrombi. Our study found that a novel material, ES-PMMA bone cement, can reduce local thrombosis. We used a simple and reproducible animal model to confirm the reduction in local thrombosis and explored the associated molecular mechanism. Methods: New Zealand rabbits, which were used to model thrombosis using extracorporeal carotid artery shunts, were divided into the following two groups, with 3 rabbits in each group: the PMMA bone cement group and the ES-PMMA bone cement group. Four hours after modelling, experimental samples, including thrombotic and vascular tissues, were collected. Thrombotic samples from the PMMA group and ES-PMMA group were subjected to lncRNA sequencing, and a lncRNA microarray was used to screen the differentially expressed lncRNAs. The expression of thrombomodulin in endothelial cells was quantified in vascular tissue samples. Differences in the lncRNA expression profiles between the thrombotic samples of the PMMA group and ES-PMMA group were assessed by base-to-base alignment in the intergenic regions of genomes. The lncRNA-miRNA-mRNA competitive endogenous RNA (ceRNA) network was established in light of ceRNA theory. Thrombosis was observed in the PMMA group and ES-PMMA group. Results: The thrombotic weight was 0.00706 ± 0.00136 g/cm in the PMMA group and 0.00551 ± 0.00115 g/cm in the ES-PMMA group. Quantitative real-time polymerase chain reaction (RT–q-CR) and Western blotting revealed that the expression of CD40, which can regulate thrombosis in vascular endothelial cells, was significantly lower in the ES-PMMA group than in the PMMA group. High-throughput sequencing was used to identify 111 lncRNAs with lower expression in the ES-PMMA group than in the PMMA group. Through bioinformatics investigation, lncRNA MSTRG22719.16/ocu-miR-326-5p/CD40 binding sites were selected. Fluorescent in situ RNA hybridization (FISH) was performed to verify the lower expression of lncRNA MSTRG.22719.16 in vascular tissues from the ES-PMMA group. A dual-luciferase reporter gene assay was applied to verify that ocu-miR-326-5p binds the CD40 3ʹ-UTR and targets lncRNA MSTRG.22719.16. Conclusion: Compared with PMMA bone cement, ES-PMMA bone cement can reduce thrombosis through the lncRNA MSTRG.22719.16/ocu-miR-326-5p/CD40 axis.